Bacterial bloodstream infections (BBSI) are a leading cause of morbidity, mortality, and increased health care costs (31) . Staphylococci are the second most prevalent bacteria (46) . However, a smear suggesting the presence of staphylococci in a blood culture (BC) is not sufficient for the diagnosis of true BBSI before the species is identified, because coagulase-negative staphylococci (CoNS) are part of the normal skin flora and may contaminate BC bottles during venous puncture procedures. Therefore, the presence of CoNS in BCs is not usually considered clinically significant unless two or more cultures are positive (48) . By contrast, because Staphylococcus aureus is intrinsically virulent, its isolation in only one BC bottle is usually enough to diagnose BBSI and initiate antibiotic therapy (18) .
Since the first appearance of methicillin-resistant S. aureus (MRSA) strains in 1960, they have become a serious problem worldwide (14) . BBSI due to MRSA may account for up to 30% of all S. aureus BBSI (9) . However, vancomycin, the antibiotic treatment of choice for MRSA infections, is less effective than oxacillin for treating infections caused by methicillin-susceptible S. aureus (MSSA) (6, 40, 49) and therefore cannot be used to treat all S. aureus infections. In addition, the indiscriminate use of glycopeptides may facilitate the emergence of S. aureus strains with decreased susceptibility or resistance (35) .
Two questions, therefore, arise when clusters of gram-positive cocci, suggesting the presence of staphylococci, are first detected on a smear from a positive BC bottle: (i) is the organism S. aureus or CoNS, and (ii) is it susceptible to methicillin? Conventional bacteriologic methods require 24 to 48 h to answer these questions. Several faster methods of differentiating between S. aureus and CoNS in BC bottles in 150 to 250 min have been assessed (7) , but their results do not indicate whether or not the strain is susceptible to methicillin. Direct real-time PCR (RT-PCR) in BC-positive bottles has been used to detect the mecA gene encoding PBP2a, which causes methicillin resistance, but as stated above, it does not differentiate CoNS from S. aureus (8) . A duplex RT-PCR detecting the mecA gene and Sa442 (36) or the nuc (43) or femA gene (1) specific for S. aureus has been proposed to do it, but its efficacy has not been evaluated when used with the different commercially available BC bottles, some of which include potential PCR inhibitors like resins (1, 36) or charcoal particles (43) . In our study, we used a triplex RT-PCR, which avoids these problems by targeting femA and mecA genes as well as an rrs sequence specific for staphylococci. We assessed its efficacy with the main types of BC bottles currently used by most microbiology laboratories and evaluated its potential ability to improve the effectiveness of antibiotic treatment.
MATERIALS AND METHODS
The study was undertaken in four French teaching hospitals located in the Paris, France, area (1,100, 670, 580, and 540 beds, respectively). BC bottles from two of these hospitals were processed using the Bactec 9240 system (BectonDickinson, Le Pont-De-Claix, France), those from another using the BacT/Alert 3D system (bioMérieux, Marcy l'Etoile, France) with charcoal, and those from the remaining hospital using the latter system but without charcoal.
The types of BC bottles used were Lytic/10 Anaerobic/F and Plusϩ Aerobic/F bottles (Becton-Dickinson). All patients over 18 years of age whose BCs were positive for clustered gram-positive cocci on direct smear examination (DSE) between 1 March and 31 August 2004 were included in the study. When a patient had more than one positive BC, only the first was included.
One milliliter of the contents of each bottle included was stored at Ϫ20°C, and the bottle was then processed using standard bacteriologic techniques. Differentiation between S. aureus and CoNS was based on the results of the rabbit plasma coagulase test (bioMérieux) and Slidex Staph Plus kit (bioMérieux), and the results were interpreted as described previously (37) . Isolate susceptibility to antibiotics, including methicillin, was then determined by the diffusion method (44) and was interpreted as described previously (2) . The results of the phenotypic techniques were reported to clinicians according to standard procedures.
One of the investigators visited the patients concerned in their clinical wards and recorded the following information: age, gender, type of infection (community or nosocomial), source of infection, ongoing treatments, therapeutic changes made upon transmission of the phenotypic results, and in-hospital deaths.
The portal of entry was defined as a localized focus of staphylococcal infection preceding bacteremia. Catheter-related staphylococcal bacteremia was defined according to the following criteria: (i) evidence of phlebitis or inflammation at the insertion site and/or (ii) the presence of staphylococci with the same antibiotic susceptibility pattern on semiquantitative catheter tip cultures and no evidence of another source of infection (21) . CoNS bacteremia was considered a true BBSI if at least two BCs within 5 days were positive for the same isolate (CoNS isolates of each BC were considered the same when they had identical antibiotic susceptibility patterns) or if one BC was positive and the patient exhibited clinical evidence of infection, including abnormal white blood cell counts, temperature, or blood pressure (3). Staphylococcal bacteremia was classified as nosocomial if the result of the first BC was positive and if clinical evidence of infection developed later than 48 h after admission, or it was classified as community-acquired or of unknown origin when data were omitted.
The efficacy of antibiotic therapy was classified as optimal, suboptimal, or nonoptimal with regard to the antibiotics used and according to the staphylococcal species isolated and its susceptibility to methicillin. For MSSA, treatment with oxacillin or an expanded-spectrum or broad-spectrum cephalosporin or with ␤-lactamin combined with a ␤-lactamase inhibitor was classified as optimal, treatment with glycopeptides (except in cases of allergy to ␤-lactam) was suboptimal, and treatment with an antibiotic to which the isolate was not susceptible was nonoptimal. For methicillin-resistant staphylococcal BBSI, treatment was classified as optimal when glycopeptides were used and as nonoptimal otherwise.
The frozen aliquots from positive BC bottles were all taken to the same laboratory for analysis by triplex RT-PCR assay. They were defrosted in batches at room temperature, and DNA was directly extracted by a rapid procedure requiring a maximum of 10 min using the DiagHemoc-Staph kit (Diagenode, Liege, Belgium). Briefly, 20 l of each aliquot was dropped into tubes containing 1 ml of sterile, distilled, deionized water and 50 l of glass beads. The tubes were incubated for 1 min at room temperature. The suspensions were then centrifuged at 16,000 ϫ g for 1 min, and the pellets were resuspended in 100 l of lysis buffer and vigorously stirred by vortexing. Nine hundred microliters of RNase/DNasefree water (Sigma-Aldrich, Saint Quentin Fallavier, France) was then added to each tube, and the tubes were spin centrifuged at 16,000 ϫ g.
Triplex RT-PCRs were processed on ABI Prism 7000 sequence detection systems (Applera, Courtaboeuf, France). The primer sequences used for the amplification of the mecA gene, the femA gene of S. aureus, and the signature of staphylococci in the rrs gene and the hybridization probes used are given in Table  1 . Triplex RT-PCR was performed with a total volume of 25 l, containing 2.5 l of master mix PCR buffer, 1 l of primer and probe mix (Diagenode), and 2 l of template DNA, prepared as described above. Thermocycling conditions were as follows: 2 min at 50°C and 10 min at 95°C, followed by 35 cycles of 15 s at 95°C and 40 s at 60°C. The full thermocycling procedure lasted 84 min. RNase/DNasefree water (Sigma) was used with each batch of samples as a negative control, and positive organisms and purified DNA from MRSA (ATCC 43868) and MSSA (ATCC 25923) were used as positive controls. The cutoff limit of detection, determined for serially purified DNA dilutions, was approximately 100 DNA copies of each target per sample (data not shown).
The study has been approved by our institutional review board.
RESULTS
The first BC bottles with clustered gram-positive cocci on DSE from 410 patients (respectively, 111, 59, 73, and 167 from each of the four participating hospitals), were included in the study. The patients comprised 243 males (59%) and 167 females (41%), and their mean age was 58 years (0 to 100). Thirty-four (8%) were hospitalized in surgery wards, 250 (61%) in medical wards, and 126 (31%) in intensive care units (ICU). The results of the standard identification methods showed that 31 BCs (7.6%) were positive for MRSA, 66 (16%) for MSSA, 1 (0.2%) for both MRSA and MSSA, 188 (46%) for methicillin-resistant CoNS (MR-CoNS), 113 (27.5%) for methicillin-susceptible CoNS (MS-CoNS), 4 (1%) for both MRCoNS and MS-CoNS, and 7 (1.7%) for Micrococcus spp.
The results of the triplex RT-PCR compared to those for the phenotypic species identification and methicillin susceptibility determination methods are shown in Table 2 . The femA gene was detected in all the BCs which contained S. aureus (n ϭ 98) but in none of those which did not (n ϭ 312). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the triplex RT-PCR for the detection of S. aureus were therefore all 100%. The mecA gene was detected in 31 BCs containing MRSA, 1 BC containing a BCs in which the only species isolated by the phenotypic techniques was MS-CoNS. However, by PCR performed with DNA extracted from the colonies, these four isolates were positive for mecA and were therefore classified as MR-CoNS and not MS-CoNS. Consequently, the sensitivity and PPV of the triplex RT-PCR for the detection of MR staphylococci were 100% and the specificity and NPV were greater than 100% compared to those of the phenotypic techniques. The rrs signature for staphylococci was detected in all the BCs containing staphylococci (n ϭ 403) but in none containing Micrococcus spp. Therefore, the sensitivity, specificity, PPV, and NPV of the triplex RT-PCR for the detection of staphylococci were all 100%. Clinical characteristics were not recorded for 37 patients. (Fig. 1A) . This treatment was retrospectively judged nonoptimal in 19 (28%), suboptimal in 10 (15%), and optimal in 39 (57%) (Fig. 1A) . After the transmission of the DSE results to clinicians, several changes occurred. First, 13 of the 19 nonoptimal treatments were changed to optimal ones and 1 to a suboptimal one, and 5 remained nonoptimal. After the full species and methicillin susceptibility were determined 24 to 48 h later by standard techniques, further changes were observed in this group of patients. In the end, all primitively nonoptimal treatments had ultimately been changed to optimal ones. Second, among the 10 patients whose initial treatments were suboptimal, 2 were switched to optimal ones after the DSE results were available, and a total of 6 were so treated after all phenotypic results were available. Four remained suboptimally treated. Last, changes in the 39 patients whose treatments were initially optimal resulted in switches to suboptimal ones for 9 after their DSE results were known, but for all of the 9, the treatment was indeed readjusted to an optimal treatment after their full phenotypic results were known. The details on the bacterial species isolated in each category of patients are shown in Fig. 1A .
Disclosure of the DSE results also induced major changes in the care of 53 (44%) of the 121 true BBSI patients who had not been treated until then (Fig. 1B) . Optimal treatments were initiated in 31 (58%) of them, while 14 received suboptimal treatments and 1 nonoptimal treatment; meanwhile, 7 patients remained untreated. After the full phenotypic results were known, the number of patients treated optimally increased to 51, the last 2 remaining suboptimally treated (see Fig. 1B for the details on the bacterial species isolated in each patient category).
Altogether, when considering all of the 121 patients with true BBSI (Fig. 1A and B) , 76 (63%; 29 with MSSA, 24 with MRSA, 6 with MS-CoNS, and 17 with MR-CoNS) received optimal treatment after the DSE results were known, and the number climbed to 115 (95%; 55 with MSSA, 29 with MRSA, 13 with MS-CoNS, and 18 with MR-CoNS) when all of the phenotypic results became available 24 to 48 h later. No patient remained untreated, but six (two with MSSA and four with MS-CoNS) were still treated suboptimally then.
We evaluated the potential impact of the faster triplex RT-PCR results by comparing the ideal treatments that could have been initiated immediately after obtaining the DSE results if the triplex RT-PCR results had been available to the treatments actually chosen once the complete phenotypic results were known.
First, earlier knowledge of the triplex RT-PCR results could have prevented the overtreatment of three patients without true BBSI who had only one CoNS-positive BC but for whom antibiotics were actually initiated (two with vancomycin and one with oxacillin; results not shown) after disclosure of the results of the DSE and were continued until their phenotype identifications were known 48 h later.
Second, when we analyzed the 121 patients with true BBSI, we observed that for the 68 patients already treated (Fig. 1A) when their BCs were diagnosed positive, the following increases in treatment adequacy could have been made: (i) the 19 with nonoptimal treatment could have all received optimal treatment immediately instead of in a delayed manner, as for 6 of them, (ii) it could have been the 
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same for at least 4 of the 8 of them with initial suboptimal treatment (for the 4 others, the treatment remained suboptimal even when the full phenotypic results were known), and (iii) the unwise transient changes from optimal to suboptimal treatments observed for 9 of the 39 patients with initial optimal treatment could have been avoided. Also, in the remaining 53 patients with true BBSI who were not already treated (Fig. 1B) when their BCs were diagnosed positive, we observed that treatment adequacy could have been increased for at least 20 of the 22 for which the treatment initiated after the DSE results were known was not optimal (for the 2 others, the treatment remained actually suboptimal even when the full phenotypic results were known). 
DISCUSSION
Our results showed that triplex RT-PCR would help to make early decisions that would improve the treatment of patients exhibiting a first positive BC with gram-positive cocci in clusters on DSE. RT-PCR results were available in less than 90 min, and the assay was both sensitive and specific, with much higher predictive values than those given by the phenotypic techniques currently used in clinical laboratories. The proper use of triplex RT-PCR results by the clinicians could have allowed better treatment of at least 31 (36%) of the 86 patients infected by S. aureus and 8 (23%) of the 35 infected by CoNS.
This striking finding was due to the fact that it is often difficult to make appropriate therapeutic decisions when the first positive BC of a given patient has clustered gram-positive cocci on DSE because the currently used phenotypic techniques do not provide information on species identification and antibiotic susceptibility in less than 24 to 48 h. Previously, we showed that under these conditions, a time to positivity (TTP) shorter than 9 h was highly predictive of the presence of S. aureus and that a TTP longer than 18 h was predictive of the presence of CoNS (33) . However, as 50% of BCs with S. aureus have a TTP longer than 9 h (33), the information supplied by the TTP is often limited. Rapid phenotypic techniques and peptide nucleic acid fluorescence in situ hybridization (28) have been developed to provide information on the staphylococcal species present in less than 150 to 250 min after DSE (7), without waiting for culture and identification results. However, these tests provide no information on isolate susceptibility to methicillin. The detection of methicillin resistance by showing the presence of the PBP2a protein by using tests designed for use with colonies grown on agar has poor sensitivity when these tests are used with BC bottles (8) . The triplex RT-PCR we tested had none of these drawbacks, as it was highly sensitive and specific for both species identification and methicillin susceptibility determination, and produced results faster than any other method so far described.
Compared to the DNA-based methods proposed by others, the extraction method that we used had the major advantages of being fast, simple, and 100% effective in obtaining sufficient quantities of DNA for triplex RT-PCR. Others have proposed techniques that result in cleaner and higher yields of target DNA (12, 29, 30, 42, 43) , but the extraction procedure we used was obviously good enough to enable our test to produce excellent results, probably because bacterial counts in positive BCs are very high (23) , and therefore, the sensitivity limit of the technique in terms of the amount of DNA detected is not critical. In addition, these alternative techniques are either more time consuming or more expensive than the one used in our study. Several conventional triplex PCRs (23, 24) , as well as a duplex RT-PCR (1, 4, 30, 36, 43) , have been developed for the concomitant detection of MSSA, MRSA, MR-CoNS, and MSCoNS in BCs, but we were apparently the first to use a triplex RT-PCR assay. Recently, a multiplex RT-PCR focusing on the identification of MRSA/SA has been proposed (39) . However, it did not specifically identify CoNS, and the assay performances were less accurate than in our study (15, 39) . Two of three targets, femA and rrs, have long been effective for differentiating CoNS from S. aureus (1, 11, 20, 30) and so has mecA for detecting methicillin resistance (19, 45) . The drawback of the combined use of these three probes is their inability to differentiate between mixed cultures of MSSA and MR-CoNS and of MRSA and MS-CoNS, but such combinations are rare in BCs (there were none in our study and less than 1% in other studies) (1, 38) . Neither can mixtures of MSSA and MRSA be differentiated from pure MRSA cultures, but this is of little clinical importance because such cases are also very rare (1/410 [0.2%] in our study), and they must be treated in the same way as MRSA infections.
In practice, PCR results should be transmitted to clinicians as soon as they are available to maximize chances of adapting treatment early. In the laboratory, the test could be run on each specimen, or a batch approach could be used, which could, however, decrease its impact in terms of patient care.
The use of the RT-PCR described here could have increased the rates of treatment adequacy, first, because it could have led to better and earlier treatment of patients who were initially given nonoptimal antibiotic regimens or who remained untreated although they were in fact infected (the latter group mostly comprised S. aureus patients) and, second, because it could have helped clinicians to refrain from treating the patients not actually suffering from an infection, most of whom had BCs contaminated by CoNS but were not in fact infected.
Of the 86 patients from our study with true S. aureus BBSI, 10 (11%) had still not been adequately treated 24 to 48 h after the DSE results were known (5 patients were untreated, and 5 had been given nonoptimal treatments). It is known that for ICU patients with S. aureus BBSI, treatment inadequacy can reach 30% (16, 47) , a figure that might rise even higher with the spread of the current epidemic of community-acquired MRSA infections (26) . Because delayed treatment can increase the rates of prolonged hospitalization (22) and of secondary metastatic infections, such as endocarditis (10, 34) and vertebral osteomyelitis (17) , the use of triplex RT-PCR should reduce both of these unwholesome events by optimizing early treatments. Another retrospective study has also shown that there was a high percentage of patients nonoptimally treated (42) . The value of the PCR has also been shown in a prospective, however small, study (13) . We found that only 35 (12%) of 121 patients with CoNSpositive BCs were actually infected and that 8 (23%) of them were not initially given optimal treatment (2 were untreated, 1 was given a nonoptimal treatment, and 5 a suboptimal treatment). These patients might also have benefited from the early results of our assay, although the impact of delayed treatment on patients infected by CoNS has never, to our knowledge, been quantified. Our result is in agreement with those reported by others (13) .
The 21 (36.8%) patients of 57 with MSSA who received suboptimal vancomycin and were switched to optimal treatments only 24 to 48 h after the results of the DSE were known would also have benefited from earlier results. This result is in agreement with those of other studies (13, 42) . The early use of optimal ␤-lactams, especially oxacillin, is important because they are more rapidly bactericidal than glycopeptides on staphylococci in vitro (25) , resulting in better clinical efficacy in patients with MSSA endocarditis (6) and in hemodialyzed patients suffering from MSSA bacteremia (40) .
The same might be true of the five patients given vancomycin who were infected with MS-CoNS. Our result is in agreement with those described by others (13) . However, for these patients, the benefit from early triplex RT-PCR results is more hypothetical because no data proving that early oxacillin is clinically beneficial for MS-CoNS patients are available.
The last group of patients who might have benefited from the early results of the triplex RT-PCR were the three with BC-positive CoNS who were not actually infected but were given antibiotics unnecessarily for 24 to 48 h before phenotypic results were known. The same observation was also reported elsewhere (42) . For these patients, the risks of allergy and unjustified selective pressure could have been avoided.
In all, triplex RT-PCR could have prevented the treatment of 28 patients (including 26 [21%] of the 121 with true BBSI and 2 [8%] of the 252 with false BBSI) with glycopeptides and the associated risk of the emergence of glycopeptide resistance in enterococci (27, 32) , as well as the risk of either decreased susceptibility to glycopeptides or glycopeptide resistance in staphylococci (5) . Obviously, the clinical usefulness of this test may depend on the patient case mix and local rates of appropriate empirical therapy for septic patients. In summary, the RT-PCR described here looks very promising. Its widespread use might well lead to a significant improvement in the immediate care of patients with a first BC exhibiting clustered grampositive cocci upon DSE, a common medical problem which has not so far been completely solved. However, because of the retrospective nature of this work, the results should be confirmed in a prospective study.
